In a report released on October 6, Pablo Zuanic from Cantor Fitzgerald reiterated a Buy rating on Cresco Labs (CRLBF – Research Report), with a price target of $15.00. The company’s shares closed last Friday at $3.43.
According to TipRanks, Zuanic is ranked #1112 out of 7862 analysts.
Cresco Labs has an analyst consensus of Strong Buy, with a price target consensus of $8.09.
See today’s best-performing stocks on TipRanks >>
CRLBF market cap is currently $1.4B and has a P/E ratio of -2.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cresco Labs Inc is a Canada based company engaged in the production and sale of cannabis. The company distribute its products to dispensaries nationwide, including several dispensaries owned and operated by its team. Its product includes Reserve, Remedi, Mindy’s. All the revenues of the company were generated in the United States. It has ownership interests in Illinois, Pennsylvania, Ohio, California, Maryland, and Arizona.
Read More on CRLBF:
